Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
licensing
Podcast
The deal before the deal
Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.
Ayla Ellison
,
James Waldron
Jun 26, 2026 9:20am
A 5-month sprint: Inside Pfizer's $10B deal with Innovent
Jun 21, 2026 10:41pm
AbbVie, Gilead gift themselves clinical-stage cancer drugs
Jan 2, 2026 10:35am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
AbbVie exercises $40M option for Capsida-partnered gene therapy
Jan 7, 2025 10:45am
